December 20, 2020

Global Big Data in the Healthcare & Pharmaceutical Market Competition, Opportunities and Challenges 2030

Summary - A new market study, titled "Big Data in the Healthcare & Pharmaceutical Industry: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts" has been featured on WiseGuyReports.

“Big Data” originally emerged as a term to describe datasets whose size is beyond the ability of traditional databases to capture, store, manage and analyze. However, the scope of the term has significantly expanded over the years. Big Data not only refers to the data itself but also a set of technologies that capture, store, manage and analyze large and variable collections of data, to solve complex problems.

ALSO READ: https://www.wfmj.com/story/42346791/big-data-in-healthcare-pharmaceutical-market-2020-strategy-analysis-business-overview-and-opportunities-to-2030

Amid the proliferation of real-time and historical data from sources such as connected devices, web, social media, sensors, log files and transactional applications, Big Data is rapidly gaining traction from a diverse range of vertical sectors. The healthcare and pharmaceutical industry is no exception to this trend, where Big Data has found a host of applications ranging from drug discovery and precision medicine to clinical decision support and population health management.

SNS Telecom & IT estimates that Big Data investments in the healthcare and pharmaceutical industry will account for nearly $4.7 Billion in 2018 alone. Led by a plethora of business opportunities for healthcare providers, insurers, payers, government agencies, pharmaceutical companies and other stakeholders, these investments are further expected to grow at a CAGR of approximately 12% over the next three years.

The “Big Data in the Healthcare & Pharmaceutical Industry: 2018 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of Big Data in the healthcare and pharmaceutical industry including key market drivers, challenges, investment potential, application areas, use cases, future roadmap, value chain, case studies, vendor profiles and strategies. The report also presents market size forecasts for Big Data hardware, software and professional services investments from 2018 through to 2030. The forecasts are segmented for 8 horizontal submarkets, 5 application areas, 37 use cases, 6 regions and 35 countries.

The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.

Topics Covered

The report covers the following topics:

- Big Data ecosystem

- Market drivers and barriers

- Enabling technologies, standardization and regulatory initiatives

- Big Data analytics and implementation models

- Business case, application areas and use cases in the healthcare and pharmaceutical industry

- Over 40 case studies of Big Data investments by healthcare providers, insurers, payers, pharmaceutical companies and other stakeholders

- Future roadmap and value chain

- Profiles and strategies of over 270 leading and emerging Big Data ecosystem players

- Strategic recommendations for Big Data vendors, and healthcare and pharmaceutical industry stakeholders

- Market analysis and forecasts from 2018 till 2030

Forecast Segmentation

Market forecasts are provided for each of the following submarkets and their subcategories:

Hardware, Software & Professional Services

- Hardware

- Software

- Professional Services

Horizontal Submarkets

- Storage & Compute Infrastructure

- Networking Infrastructure

- Hadoop & Infrastructure Software

- SQL

- NoSQL

- Analytic Platforms & Applications

- Cloud Platforms

- Professional Services

Application Areas

- Pharmaceutical & Medical Products

- Core Healthcare Operations

- Healthcare Support, Awareness & Disease Prevention

- Health Insurance & Payer Services

- Marketing, Sales & Other Applications

Use Cases

- Drug Discovery, Design & Development

- Medical Product Design & Development

- Clinical Development & Trials

- Precision Medicine & Genomics

- Manufacturing & Supply Chain Management

- Post-Market Surveillance & Pharmacovigilance

- Medical Product Fault Monitoring

- Clinical Decision Support

- Care Coordination & Delivery Management

- CER (Comparative Effectiveness Research) & Observational Evidence

- Personalized Healthcare & Targeted Treatments

- Data-Driven Preventive Care & Health Interventions

- Surgical Practice & Complex Medical Procedures

- Pathology, Medical Imaging & Other Medical Tests

- Proactive & Remote Patient Monitoring

- Predictive Maintenance of Medical Equipment

- Pharmacy Services

- Self-Care & Lifestyle Support

- Digital Therapeutics

- Medication Adherence & Management

- Vaccine Development & Promotion

- Population Health Management

- Connected Health Communities & Medical Knowledge Dissemination

- Epidemiology & Disease Surveillance

- Health Policy Decision Making

- Controlling Substance Abuse & Addiction

- Increasing Awareness & Accessible Healthcare

- Health Insurance Claims Processing & Management

- Fraud & Abuse Prevention

- Proactive Patient Engagement

- Accountable & Value-Based Care

- Data-Driven Health Insurance Premiums

- Marketing & Sales

- Administrative & Customer Services

- Finance & Risk Management

- Healthcare Data Monetization

- Other Use Cases

Regional Markets

- Asia Pacific

- Eastern Europe

- Latin & Central America

- Middle East & Africa

- North America

- Western Europe

Country Markets

- Argentina, Australia, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, India, Indonesia, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Pakistan, Philippines, Poland, Qatar, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, UAE, UK, USA

Key Questions Answered

The report provides answers to the following key questions:

- How big is the Big Data opportunity in the healthcare and pharmaceutical industry?

- How is the market evolving by segment and region?

- What will the market size be in 2021, and at what rate will it grow?

- What trends, challenges and barriers are influencing its growth?

- Who are the key Big Data software, hardware and services vendors, and what are their strategies?

- How much are healthcare providers, insurers, payers, pharmaceutical companies and other stakeholders investing in Big Data?

- What opportunities exist for Big Data analytics in the healthcare and pharmaceutical industry?

- Which countries, application areas and use cases will see the highest percentage of Big Data investments in the healthcare and pharmaceutical industry?

Key Findings

The report has the following key findings:

- In 2018, Big Data vendors will pocket nearly $4.7 Billion from hardware, software and professional services revenues in the healthcare and pharmaceutical industry. These investments are further expected to grow at a CAGR of approximately 12% over the next three years, eventually accounting for more than $7 Billion by the end of 2021.

- Big Data and advanced analytics are driving a paradigm shift in the healthcare and pharmaceutical industry with multiple innovations ranging from precision medicine and digital therapeutics to the adoption of accountable and value-based care models.

- Drug developers are making substantial investments in Big Data and artificial intelligence-driven drug discovery platforms to shorten the process of successfully discovering promising compounds. In addition, Big Data technologies are increasingly being utilized to streamline clinical trials, enabling biopharmaceutical companies to significantly lower costs and accelerate productive trials.

- The growing adoption of Big Data technologies has also brought about an array of benefits for hospitals and other healthcare facilities. Based on feedback from healthcare providers worldwide, these include but are not limited to cost savings in the range of 20-30%, an increase in patient access to services by more than 35%, growth in revenue by up to 30%, a reduction in emergency room visits by 10%, a drop in patient wait times by 30-60%, improvements in outcomes by as much as 20%, a 10-50% decline in mortality rates for conditions such as heart failure, and a reduction in the occurrence of hospital acquired and surgical site infections by nearly 60%.

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3306934-big-data-in-the-healthcare-pharmaceutical-industry-2018

About Us: Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Us:

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)